Pharming Group N.V./€PHARM

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Pharming Group N.V.

Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.

Ticker

€PHARM

Primary listing

AEX

Industry

Biotechnology

Employees

404

PHARM Metrics

BasicAdvanced
€590M
-
-€0.02
0.53
-

Bulls say / Bears say

Pharming Group's total revenues increased by 21% to US$297.2 million in 2024, surpassing guidance, driven by record RUCONEST® revenue and strong Joenja® growth (pharming.com).
The acquisition of Abliva AB added KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, aligning with their vision to become a leading global rare disease company (pharming.com).
Pharming Group appointed Fabrice Chouraqui as Chief Executive Officer in March 2025, bringing extensive biopharmaceutical leadership experience to drive the company's growth (pharming.com).
Despite revenue growth, Pharming Group reported a net loss of US$11.0 million for the year ended December 31, 2024, indicating ongoing profitability challenges (pharming.com).
The company's operating profit decreased to a loss of US$8.6 million in 2024 from a loss of US$5.4 million in 2023, reflecting increased operating expenses (pharming.com).
Pharming Group's cash and cash equivalents, restricted cash, and marketable securities decreased to US$108.9 million as of March 31, 2025, from US$169.4 million at the end of 2024, potentially impacting financial flexibility (nasdaq.com).
Data summarised monthly by Lightyear AI. Last updated on 4 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €PHARM

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs